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A presumptive chromosomal cephalosporinase (pI, 9.0) from a clinical strain of Acinetobacter genomic
species 3 (AG3) is reported. The nucleotide sequence of this -lactamase shows for the first time the gene
encoding an AmpC enzyme in AG3. In addition, the biochemical properties of the novel AG3 AmpC -lacta-
mase are reported
The bacterial genus Acinetobacter consists of strictly aerobic
gram-negative coccobacilli, which are oxidase negative, non-
motile, nitrate negative, and nonfermentative.
Studies based on DNA-DNA hybridization have led to the
description of 23 DNA homology groups, or genomospecies,
within the genus Acinetobacter (5, 7, 11, 15, 21, 26). Seven
species of this genus have been named and are included in the
Index of the Bacterial and Yeast Nomenclatural Changes (19): (i)
A. calcoaceticus, or genomospecies 1; (ii) A. baumannii, or
genomospecies 2; (iii) A. haemolyticus, or genomospecies 4;
(iv) A. junii, or genomospecies 5; (v) A. johnsonii, or genomo-
species 7; (vi) A. lwoffii, or genomospecies 8; and (vii) A.
radioresistens, or genomospecies 12. Groups 1 (A. calcoaceti-
cus), 2 (A. baumannii), and the as-yet-unnamed and closely
related genomic DNA groups 3 and 13TU (often referred to as
the A. calcoaceticus-A. baumannii complex) are the most fre-
quent species among clinical isolates, particularly A. baumannii
and Acinetobacter genomospecies 3 (AG3) (5, 6, 13, 26).
Earlier studies showed statistically significant differences be-
tween the distributions in Hong Kong and Europe of genomic
DNA groups of isolates obtained from blood cultures and
various superficial carriage sites (10). Indeed, in some Hong
Kong hospitals, AG3 strains accounted for up to 40% of the
blood culture isolates (10). Antimicrobial susceptibilities also
differed significantly among members of the A. calcoaceticus-A.
baumannii complex, which indicates diversity in the molecular
mechanisms involved in the antimicrobial resistance observed
(14, 29). In keeping with this trend, A. baumannii was the most
resistant genospecies.
The most common mechanism of the resistance of A. bau-
mannii to -lactam antibiotics is attributed to the presence of
-lactamases encoded either by the chromosome or by plas-
mids (2). Several class A, B, and D -lactamases (1, 2, 3, 22, 23,
27), as well as chromosome-mediated cephalosporinases (pI,
8) (2, 3) (which confer different resistance phenotypes to A.
baumannii) have been described. However, only one ampC
gene (AmpC of RYC52763) encoding an AmpC -lactamase
(4) and two allelic variants (ABAC-1 and ABAC-2) (17) have
been reported so far for A. baumannii strains.
Regarding -lactam resistance in the AG3 group, two met-
alloenzymes, VIM-2 and IMP-4, have been identified in Hong
Kong and Korea (9, 30).
The aim of this study was to elucidate the mechanisms as-
sociated with the resistance to -lactam antibiotics shown by a
clinical strain of Acinetobacter genomic DNA group 3
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TABLE 1. MICs of -lactams for clinical strain AJC68081, E. coli
TG1, E. coli TG1 (pBE-1), and E. coli TG1 (pGER1)
Antibiotic
MIC (g/ml)a
AJC68081
(produces
AmpC of
AG3)
E. coli
TG1
E. coli TG1
(pBE-1)b
E. coli TG1
(pGER1)c
Amoxicillin 256 3 256 128
Amoxicillin 
clavulanated
6 2 24 32
Piperacillin 256 0.38 64 8
Cephalothin 256 3 256 256
Cefuroxime 256 1.5 256 256
Cefoxitin 256 2 128 2
Cefotaxime 256 0.023 2 4
Cefotaxime 
clavulanated
0.19 0.023 1 1
Ceftazidime 32 0.064 0.75 16
Ceftazidime 
clavulanated
0.19 0.064 0.5 8
Cefepime 32 0.016 0.047 0.25
Aztreonam 12 0.032 0.25 1
Imipenem 1 0.125 0.38 0.125
Meropenem 0.75 0.008 0.023 0.012
Clavulanic acid 8–16 ND ND ND
Sulbactam 16–32 ND ND ND
a ND, not done.
b Transformant producing AmpC -lactamase of AG3.
c Transformant producing AmpC -lactamase of A. baumannii.
d Clavulanate was used at 4 g/ml.
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(AJC68081) identified by amplified ribosomal DNA restriction
analysis (28) and isolated from a wound exudate of a patient
treated at the Juan Canalejo Hospitalary Complex.
The susceptibility testing of the AJC68081 strain was per-
formed by a microdilution method following the recommen-
dations of the National Committee for Clinical Laboratory
Standards (20). Antibiotics were kindly provided by their man-
ufacturers as powders of fixed potency. MICs were confirmed
by the E-test. The antibiotic susceptibility profiles of all strains
included in this study are shown in Table 1.
The -lactamases were analyzed by isoelectric focusing as
described by Matthew et al. (18). The sonicated extract of
strain AJC68081 contained a single -lactamase with a pI of ca.
9.0, which may correspond to that of a chromosomal cepha-
losporinase. Alkaline lysis of the bacteria (24) did not result in
plasmid isolation.
The possibility of a certain degree of homology between the
present AG3 cephalosporinase and the previously reported
ampC gene of A. baumannii allowed us to design oligonucle-
otides that could specifically amplify our target AG3 cephalos-
porinase gene by PCR. Chromosomal DNA from strain
AJC68081 was purified according to standard protocols (Mas-
terPure DNA purification kit; Epicentre, Madison, Wis.). Five
hundred nanograms of the AG3 chromosome was used as a
template to be amplified by PCR with the two oligonucleotides
ampC1 forward (5-TAGTATTCGTCGTTAGAAAACAAT)
and ampC2 reverse (5-GCTTAGGATATGTTTGGTTCTT)
(Sigma-Genosys Ltd., Cambridge, United Kingdom), which
hybridize in the untranslated regions of the A. baumannii
(RYC52763) ampC gene (4). The PCR was performed under
the following conditions: denaturation, 10 min at 94°C; ampli-
fication, 30 cycles of 1 min at 94°C, 1 min at 55°C, and 2 min at
72°C; and elongation, 16 min at 72°C. An aliquot (20 l) of the
sample was subjected to electrophoresis in a 1.0% agarose gel.
The gel showed an amplified product, detected by ethidium
bromide staining (50 mg/liter), of 1.3 kb, which was the ex-
pected size of the ampC gene in relation to that in A. bauman-
nii. For further analysis, the 1.3-kb amplicon was ligated into
pGEM-T easy vector (Promega Corporation, Madison,
Wis.), and the recombinant plasmids were introduced into
Escherichia coli TG1 by transformation with CaCl2 (24). The
selection of transformants on Luria-Bertani agar plates sup-
plemented with ampicillin (50 g/ml), isopropyl--D-thiogalac-
topyranoside (IPTG, 25 g/ml; Roche Diagnostics, Mannheim,
Germany), and 5-bromo-4-chloro-3-indolyl--D-galactopyr-
anoside (X-Gal, 100 g/ml; Roche Diagnostics) resulted in
several white colonies, all carrying an identical recombinant
plasmid. After alkaline lysis of the transformant (24), enzy-
matic digestion of the purified pGEM-T plasmid with EcoRI
FIG. 1. Nucleotide sequence of the 1.3-kb fragment. The amino
acid sequence deduced for AmpC G3 -lactamase is shown on the line
below the nucleotide triplets. The ATG and TAA shown in boldface
type represent the initiation and termination codons, respectively. A
putative Shine-Dalgarno (S.D.) ribosomal recognition site is indicated.
The positions of the primers used to sequence the gene and to detect
the ampC gene in several AG3 strains are indicated by arrows. The
positions of the primers used for amplification and further cloning of
the gene are indicated by discontinuous arrows. The putative sequence
of the signal peptide is indicated by boldface type and lowercase
letters. The -lactamase active site SVSK, the conserved triad KTG,
and the typical class C motif YXN are shown in boldface type (12).
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released a 1.3-kb DNA insert, confirming the success of the
cloning procedure. The nucleotide sequence of the insert was
elucidated by sequencing it with the Taq DyeDeoxiTerminator
cycle sequencing kit before analysis with an automatic DNA
sequencer (377 Abi-Prims, Perkin-Elmer). The entire se-
quence of the fragment was 1,321 bp long and contained one
open reading frame (Fig. 1) of 1,152 bp (383 amino acids long).
GenBank database searches with this open reading frame re-
vealed similarities to several class C chromosome-mediated
-lactamases (Table 2). At a protein level, the highest similar-
ities detected (98.69 to 97.65%) were with the AmpC -lacta-
mases AmpC ABAC-1, AmpC ABAC-2, and AmpC
RYC52763 from A. baumannii, respectively (4, 17). Compari-
son of the amino acids in the AmpC -lactamases of AG3 with
those in ABAC-1, ABAC-2, and AmpC RYC52763 from A.
baumannii yielded five, eight, and nine amino acid differences,
respectively (4, 17). The nucleotide sequence of the promoter
region of the gene revealed two substitutions (A to G) at
positions 21 and 53 with respect to that of ampC in A.
baumannii (4). The importance of these changes in the regu-
lation of the expression of the AmpC enzyme remains un-
known.
To determine the MICs and the biochemical properties of
the -lactamase encoded by the 1.3-kb DNA insert, the insert
was cloned in the pBGS18 plasmid (25) (which carries a
kanamycin resistance gene), resulting in the pBE-1 plasmid.
The -lactam patterns of resistance to amoxicillin, cephalothin,
cefuroxime, and cefoxitin and, to a lesser extent, amoxicillin-
clavulanic acid and piperacillin of several transformants con-
taining the pBE-1 plasmid were identical, whereas the MICs of
ceftazidime, cefotaxime, cefepime, aztreonam, and carbapen-
ems were slightly higher than those for the host E. coli TG1
strain (Table 1).
Chromosomal AmpC -lactamases may be inducible in
some gram-negative rods, and genes such as the repressor
ampR and ampD may be involved in this pathway (16). The
sequences of the flanking regions of the gene encoding the
AmpC -lactamase of A. baumannii did not show any homol-
ogy with the ampR gene. Similarly, induction experiments with
cefoxitin (at one-half the MIC) performed with the original
AJC68081 strain did not show an increase in the synthesis of
the AmpC -lactamase, measured as specific enzymatic activity
(in micromoles of nitrocefin hydrolyzed per minute per micro-
gram of protein) when the inducer was added (159  38 mol/
min/g of protein without the inducer, 145  15 mol/min/g
of protein in the presence of inducer). These experiments
indicated that the AG3 AmpC -lactamase in this strain is
noninducible.
To purify the AmpC enzyme, the blaampC gene was cloned in
the pGEX-6P-1 vector, which allows a fusion protein between
glutathione S-transferase and the AmpC enzyme. The -lacta-
mase was purified at homogeneity with the GST gene fusion
system (Amersham Pharmacia Biotech, Europe GmbH) ac-
cording to the manufacturer’s directions. With sodium dodecyl
sulfate-polyacrylamide gel electrophoresis, the purified protein
appeared as a band of ca. 40 kDa (95% purity) (data not
shown). Kinetic experiments were performed as previously de-
scribed (4). The specific activity of semipurified AmpC -lac-
tamase was 49,000 mol of nitrocefin/min/g of protein. The
relative enzymatic efficiency (Vmax/Km) values indicated that
cephalothin was hydrolyzed with higher hydrolytic efficiency
than ampicillin, as expected for a class C -lactamase (Table
3). This enzyme also showed moderate hydrolytic activity
against cefuroxime and cefoxitin and very little hydrolytic ac-
tivity against cefotaxime and imipenem; therefore, we could
not obtain reliable Km and Vmax values for these antibiotics.
Hydrolytic activity against ceftazidime was not detected. Fifty
percent inhibitory concentrations were calculated as previously
reported (4) (Table 3).
A PCR assay was performed with seven genotypically differ-
ent AG3 strains (repetitive extragenic palindromic-PCR
tested) to study the presence of the ampC gene. The reactions
were carried out with a 50-l volume of a reaction mixture
containing 20 mM Tris-HCl (pH 8.8), 100 mM potassium chlo-
ride, 2.0 mM magnesium chloride, 200 M deoxynucleotide
triphosphate, 50 pmol of each oligonucleotide, 0.5 g of the
chromosomal DNA, and 2.5 U of Ecotaq polymerase (Group
3, Vigo, Spain). The primers for the ampC-coding region, P1
forward (5-ACTTACTTCAACTCGCGACG) and P2 reverse
(5-TAAACACCACATATGTTCCG), were used in the am-
plification reaction. Amplification conditions were as follows:
10 min at 94°C, followed by 30 cycles of 1 min at 94°C, 1 min
at 50°C, and 2 min at 72°C, followed by a final step of 10 min
at 72°C. The amplified 663-bp product was resolved by elec-
trophoresis in a 1.5% (wt/vol) agarose gel containing ethidium
bromide (50 g/ml). The ampC gene was disseminated among
TABLE 2. Percent identity between amino acid sequences of AG3 AmpC and other class C -lactamases
-Lactamasea
% Identity with:
AG3 AmpC A. baumanniiAmpC
Aeromonas
hydrophila
AmpC
CMY-1
Serratia
marcescens
AmpC
Aeromonas
sobria
AmpC
FOX-5 Pseudomonas aeruginosaAmpC
AG3 AmpC 100 97 46 45 45 44 44 42
A. baumannii AmpC 100 46 45 43 44 43 40
A. hydrophila AmpC 100 82 48 79 75 57
CMY-1 100 48 77 72 56
S. marcescens AmpC 100 48 49 50
A. sobria AmpC 100 77 56
FOX-5 100 55
P. aeruginosa AmpC 100
a EMBL accession numbers: AG3 AmpC, CAE00827; A. baumannii AmpC, CAB77444; A. hydrophila AmpC, CAB76925; CMY-1, CAA63264; S. marcescens AmpC,
CAB69829; A. sobria AmpC, CAA56561; FOX-5, AAG12974; P. aeruginosa AmpC, AAM08943.
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all of the AG3 isolates (data not shown). This result strongly
suggests that AmpC -lactamase may play a role in the -lac-
tam resistance of AG3. Moreover, sequence identities among
the ampC genes of the seven AG3 isolates studied were be-
tween 85 to 95% with respect to the ampC gene of A. bauman-
nii.
The susceptibility of the clinical strain of AJC68081 to the
combination of cefotaxime and ceftazidime with clavulanic
acid is also remarkable (with a clavulanic acid MIC of 8 to 16
mg/liter [Table 1]). This unusual phenomenon has been de-
tected in several strains of A. baumannii and AG3 and is
independent of the presence of any extended-spectrum -lac-
tamases, which are well inhibited by clavulanic acid (8). It is
thought that this finding may be related to penicillin-binding
protein alterations which increase the susceptibility to clavu-
lanic acid (unpublished data).
Another important consideration is the role of the -lacta-
mase under study in resistance to -lactams in AG3. The MICs
for clinical strain AJC68081 were higher than those for the E.
coli transformant expressing the G3 AmpC enzyme (Table 1).
An explanation for this result could be that other antibiotic
resistance mechanisms, such as a loss or a reduction of porin
expression, a constitutively basal expression of some efflux
pump, or penicillin-binding protein modifications, operate at
the same time in A. baumannii and/or AG3, as no other -lac-
tamases have been detected in clinical strain AJC68081.
The results obtained in the present study show that this
AmpC -lactamase (i) may play an important role in -lactam
resistance in AG3, (ii) was not inducible when cefoxitin was
added (at one-half the MIC) and thus can be considered non-
inducible, and (iii) shows a typical cephalosporinase substrate
profile, corresponding to that of a class C -lactamase.
In summary, we report for the first time the cloning, se-
quencing, and analysis of the ampC gene and the biochemical
characterization of the AmpC -lactamase from a clinical
strain of AG3.
Nucleotide sequence accession number. The GenBank ac-
cession number for the AmpC -lactamase of AG3 is
AJ575184.
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